Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.
) pushed the Health Care sector lower today making it today's featured Health Care laggard. The sector as a whole closed the day up 1.3%. By the end of trading, Cubist Pharmaceuticals fell $2.00 (-2.8%) to $68.76 on light volume. Throughout the day, 955,665 shares of Cubist Pharmaceuticals exchanged hands as compared to its average daily volume of 1,275,400 shares. The stock ranged in price between $68.35-$71.09 after having opened the day at $70.71 as compared to the previous trading day's close of $70.76. Other companies within the Health Care sector that declined today were:
), down 39.9%,
), down 16.0%,
), down 9.5% and
), down 8.8%.
- EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass
Cubist Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of pharmaceutical products for various medical needs in the acute care environment in the United States. Cubist Pharmaceuticals has a market cap of $4.9 billion and is part of the drugs industry. The company has a P/E ratio of 204.7, above the S&P 500 P/E ratio of 17.7. Shares are up 55.8% year to date as of the close of trading on Monday. Currently there are 10 analysts that rate Cubist Pharmaceuticals a buy, no analysts rate it a sell, and 6 rate it a hold.
TheStreet Ratings rates
. The company's strengths can be seen in multiple areas, such as its revenue growth, expanding profit margins and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and weak operating cash flow.
- You can view the full Cubist Pharmaceuticals Ratings Report.
On the positive front,
), up 72.9%,
), up 29.8%,
), up 19.1% and
), up 13.2% , were all gainers within the health care sector with
) being today's featured health care sector leader.
- Use our health care section to find sector-relevant news.
- Or find some new ideas from our top rated stocks lists.
For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider
) while those bearish on the health care sector could consider
- Find other investment ideas from our top rated ETFs lists.